Literature DB >> 26827658

Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease.

Jae Jung Lee1, Jungsu S Oh2, Jee H Ham1, Dong H Lee1, Injoo Lee2, Young H Sohn1, Jae S Kim2, Phil Hyu Lee3.   

Abstract

Several antecedent studies had reported close relationship between low body weight and Parkinson's disease (PD). However, there have been few investigations about the role of body weight to nigrostriatal dopaminergic neurodegeneration. This study enrolled 398 de novo patients with PD whom underwent [18F] N-(3-Fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography scan and body mass index (BMI) measurement. The relationships between BMI and dopamine transporter (DAT) activity were analyzed using linear regression analysis. A multivariate analysis adjusted for age, gender, disease duration, smoking status, coffee and tea consumption, and residence area revealed that BMI remained independently and significantly associated with DAT activity in all striatal subregions. Moreover, multiple logistic regression analyses showed that BMI was a significant predictor for the lowest quartile of DAT activity in the anterior putamen, ventral striatum, caudate nucleus, and total striatum. The present findings suggest that a low BMI might be closely associated with low density of nigrostriatal dopaminergic neurons in PD, which could support the evidence for the role of low body weight to PD-related pathologies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Body mass index; Dopamine transporter activity; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 26827658     DOI: 10.1016/j.neurobiolaging.2015.11.009

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  7 in total

1.  Prediction of future weight change with dopamine transporter in patients with Parkinson's disease.

Authors:  Kyoungjune Pak; Heeyoung Kim; Ju Won Seok; Myung Jun Lee; Seunghyeon Shin; Keunyoung Kim; Jae Meen Lee; Youngduk Seo; Bum Soo Kim; Sungmin Jun; In Joo Kim
Journal:  J Neural Transm (Vienna)       Date:  2019-05-17       Impact factor: 3.575

2.  Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.

Authors:  Han Soo Yoo; Seok Jong Chung; Su Jin Chung; Hyojeong Moon; Jung Su Oh; Jae Seung Kim; Jin Yong Hong; Byoung Seok Ye; Young Ho Sohn; Phil Hyu Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-26       Impact factor: 9.236

Review 3.  Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects.

Authors:  Kai Ma; Nian Xiong; Yan Shen; Chao Han; Ling Liu; Guoxin Zhang; Luxi Wang; Shiyi Guo; Xingfang Guo; Yun Xia; Fang Wan; Jinsha Huang; Zhicheng Lin; Tao Wang
Journal:  Front Aging Neurosci       Date:  2018-01-19       Impact factor: 5.750

4.  Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?

Authors:  M A Qamar; A Sauerbier; M Politis; H Carr; P Loehrer; K Ray Chaudhuri
Journal:  NPJ Parkinsons Dis       Date:  2017-01-25

Review 5.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

6.  Untangling the relationship between fat distribution, nutritional status and Parkinson's disease severity.

Authors:  Maria S Pisciotta; Domenico Fusco; Giulia Grande; Vincenzo Brandi; Maria R Lo Monaco; Alice Laudisio; Graziano Onder; Anna R Bentivoglio; Diego Ricciardi; Roberto Bernabei; Giuseppe Zuccalà; Davide L Vetrano
Journal:  Aging Clin Exp Res       Date:  2019-03-15       Impact factor: 3.636

Review 7.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.